Short answer
No, psilocybin is not considered addictive. It doesn't produce compulsive drug-seeking, physical dependence, or withdrawal, and a formal review of its abuse potential concluded the risk is low. Tolerance builds so quickly that taking it on back-to-back days produces much weaker effects, which makes frequent use self-limiting. Psychological risks still exist, and patterns of heavy use deserve attention.
Key takeaways
- A formal abuse potential review rated psilocybin low risk for addiction.
- There's no recognized withdrawal syndrome.
- Tolerance develops within days and fades over roughly one to two weeks.
- Psilocybin is being studied as a treatment for alcohol and tobacco addiction.
What the research says about abuse potential
When a drug is considered for rescheduling, regulators evaluate it against eight factors in the Controlled Substances Act, including its potential for abuse and dependence. In 2018, Johns Hopkins researchers ran psilocybin through that exact framework. Their conclusion: psilocybin has low potential for abuse and physical dependence, and if it's approved as a medicine, Schedule IV would be appropriate. That's the same tier as common sleep aids.1
A few reasons it scores so low:
- It doesn't hijack the reward system the way opioids, nicotine, or cocaine do.
- The experience is long and demanding. Four to six hours of intense introspection isn't something most people crave daily.
- There's no withdrawal. Stopping doesn't produce physical symptoms.2
When independent experts ranked 20 drugs on a combined scale of harm to users and others, magic mushrooms came in as the least harmful of all of them, with the lowest score for dependence.3
Why tolerance builds so fast
Use psilocybin two days in a row and the second experience will be noticeably weaker. Keep going and it fades to almost nothing. That happens because repeated activation causes your brain to pull 5-HT2A receptors off the surface of neurons, so there's less for psilocin to act on.2
Tolerance generally fades over roughly one to two weeks. It also crosses over to other classic psychedelics like LSD and mescaline, since they work on the same receptor. The practical effect is a built-in speed bump: the drug becomes less rewarding the more often you take it.
The plot twist: psilocybin for addiction
Some of the most exciting research on psilocybin is about treating addiction. In a 2022 randomized trial in JAMA Psychiatry, people with alcohol use disorder who received psilocybin with therapy had heavy drinking days on 9.7% of days over the following eight months, versus 23.6% for the placebo group.4 Early studies in smoking cessation have also been promising. See psilocybin for addiction.
Risks that remain
Low addiction potential isn't the same as no risk. The main concerns with psilocybin are psychological reactions, risky behavior while impaired, and interactions with other substances or medications.5 People who find themselves using any substance to escape problems, or more often than they intended, should take that seriously regardless of what the substance is. For the full picture, read psilocybin side effects and who should avoid it.
Common questions
Can you get psychologically addicted to shrooms?
Compulsive use of psilocybin is rare, and the experience itself tends to discourage casual repetition. That said, anyone can develop an unhealthy relationship with a substance, especially when it's used to avoid problems. If use feels out of control, talk to a professional.
Is psilocybin tolerance cross-tolerant with LSD?
Yes. Because both act on the same serotonin 2A receptors, tolerance to one reduces the effects of the other for a period of days.
Do people who microdose build tolerance?
Frequent repeated dosing can build some tolerance, which is one reason microdosing schedules people describe online include breaks. The evidence on microdosing itself is weak, as we cover in our microdosing guide.
Sources
- Johnson MW, et al. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018. doi.org/10.1016/j.neuropharm.2018.05.012
- Passie T, et al. The pharmacology of psilocybin. Addiction Biology. 2002. doi.org/10.1080/1355621021000005937
- Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010. doi.org/10.1016/S0140-6736(10)61462-6
- Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry. 2022. doi.org/10.1001/jamapsychiatry.2022.2096
- van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regulatory Toxicology and Pharmacology. 2011. doi.org/10.1016/j.yrtph.2011.01.006
This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.